Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 18 | 2022 | 322 | 3.920 |
Why?
|
| Diabetes, Gestational | 8 | 2022 | 63 | 3.630 |
Why?
|
| MicroRNAs | 5 | 2022 | 280 | 2.170 |
Why?
|
| Obesity | 7 | 2020 | 650 | 1.760 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2022 | 50 | 1.430 |
Why?
|
| Cardiovascular Diseases | 6 | 2022 | 346 | 1.400 |
Why?
|
| Exosomes | 2 | 2022 | 92 | 1.310 |
Why?
|
| Placenta | 5 | 2020 | 74 | 1.280 |
Why?
|
| Arteries | 3 | 2014 | 65 | 1.230 |
Why?
|
| Child | 21 | 2022 | 2147 | 1.050 |
Why?
|
| Adolescent | 24 | 2022 | 2957 | 1.020 |
Why?
|
| Vascular Stiffness | 6 | 2022 | 41 | 0.920 |
Why?
|
| Cell Adhesion Molecules | 2 | 2022 | 64 | 0.880 |
Why?
|
| Vascular Resistance | 2 | 2013 | 50 | 0.800 |
Why?
|
| Glycated Hemoglobin A | 3 | 2022 | 64 | 0.790 |
Why?
|
| Pregnancy | 8 | 2022 | 1131 | 0.760 |
Why?
|
| Puberty, Precocious | 1 | 2020 | 6 | 0.700 |
Why?
|
| Female | 28 | 2022 | 14462 | 0.700 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2020 | 96 | 0.700 |
Why?
|
| Puberty | 1 | 2020 | 13 | 0.700 |
Why?
|
| Fetus | 1 | 2020 | 77 | 0.690 |
Why?
|
| Hyperglycemia | 1 | 2020 | 77 | 0.670 |
Why?
|
| PPAR gamma | 1 | 2019 | 29 | 0.670 |
Why?
|
| Humans | 36 | 2022 | 26826 | 0.650 |
Why?
|
| Diabetes Complications | 2 | 2021 | 66 | 0.650 |
Why?
|
| Organelle Biogenesis | 4 | 2020 | 10 | 0.640 |
Why?
|
| Adipocytes | 1 | 2019 | 53 | 0.640 |
Why?
|
| Hypertension | 2 | 2021 | 304 | 0.610 |
Why?
|
| Blood Glucose | 7 | 2020 | 300 | 0.600 |
Why?
|
| Nerve Growth Factors | 2 | 2014 | 24 | 0.580 |
Why?
|
| Serpins | 2 | 2014 | 31 | 0.570 |
Why?
|
| Macrophages | 1 | 2019 | 273 | 0.560 |
Why?
|
| Body Composition | 3 | 2014 | 260 | 0.530 |
Why?
|
| Insulin Resistance | 5 | 2022 | 165 | 0.520 |
Why?
|
| Eye Proteins | 2 | 2014 | 197 | 0.510 |
Why?
|
| Male | 23 | 2022 | 12869 | 0.500 |
Why?
|
| Elasticity | 2 | 2013 | 49 | 0.490 |
Why?
|
| Adolescent Medicine | 1 | 2014 | 3 | 0.480 |
Why?
|
| Hyperemia | 2 | 2013 | 31 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2022 | 121 | 0.460 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 980 | 0.450 |
Why?
|
| Precision Medicine | 1 | 2014 | 67 | 0.450 |
Why?
|
| Metformin | 4 | 2021 | 32 | 0.430 |
Why?
|
| Mitochondria | 3 | 2020 | 333 | 0.400 |
Why?
|
| Diabetic Angiopathies | 4 | 2020 | 47 | 0.390 |
Why?
|
| Body Mass Index | 4 | 2022 | 386 | 0.370 |
Why?
|
| Young Adult | 9 | 2022 | 2581 | 0.360 |
Why?
|
| Adult | 11 | 2022 | 7382 | 0.350 |
Why?
|
| Risk Factors | 9 | 2022 | 2010 | 0.350 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 288 | 0.310 |
Why?
|
| Cells, Cultured | 2 | 2022 | 970 | 0.300 |
Why?
|
| Heart Rate | 4 | 2022 | 374 | 0.270 |
Why?
|
| Hypoglycemic Agents | 4 | 2021 | 105 | 0.260 |
Why?
|
| Compliance | 2 | 2014 | 21 | 0.230 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 3 | 2020 | 15 | 0.220 |
Why?
|
| Pulse Wave Analysis | 5 | 2022 | 29 | 0.220 |
Why?
|
| Age of Onset | 2 | 2020 | 68 | 0.220 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 203 | 0.200 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2022 | 20 | 0.200 |
Why?
|
| E-Selectin | 1 | 2022 | 27 | 0.200 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2022 | 57 | 0.200 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 400 | 0.180 |
Why?
|
| Trophoblasts | 2 | 2020 | 13 | 0.180 |
Why?
|
| DNA, Mitochondrial | 2 | 2020 | 82 | 0.180 |
Why?
|
| Infant | 2 | 2022 | 957 | 0.180 |
Why?
|
| Resistin | 1 | 2020 | 4 | 0.180 |
Why?
|
| Milk, Human | 1 | 2022 | 82 | 0.180 |
Why?
|
| Diabetic Nephropathies | 1 | 2020 | 19 | 0.180 |
Why?
|
| Glucose | 1 | 2022 | 191 | 0.180 |
Why?
|
| Biomarkers | 3 | 2020 | 733 | 0.180 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 40 | 0.180 |
Why?
|
| Pregnancy in Diabetics | 1 | 2020 | 21 | 0.170 |
Why?
|
| High-Intensity Interval Training | 1 | 2020 | 9 | 0.170 |
Why?
|
| Mitochondrial Proteins | 2 | 2017 | 72 | 0.170 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2019 | 5 | 0.170 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 21 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2020 | 857 | 0.170 |
Why?
|
| 3T3-L1 Cells | 1 | 2019 | 27 | 0.170 |
Why?
|
| Scientific Misconduct | 1 | 2019 | 9 | 0.170 |
Why?
|
| Trust | 1 | 2019 | 21 | 0.160 |
Why?
|
| Endothelium, Vascular | 1 | 2022 | 305 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2020 | 843 | 0.160 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 74 | 0.160 |
Why?
|
| Insulin-Secreting Cells | 1 | 2018 | 10 | 0.160 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 118 | 0.160 |
Why?
|
| Diabetic Retinopathy | 1 | 2020 | 108 | 0.160 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 57 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 144 | 0.160 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2018 | 16 | 0.160 |
Why?
|
| Up-Regulation | 1 | 2019 | 240 | 0.160 |
Why?
|
| Monitoring, Ambulatory | 1 | 2018 | 26 | 0.150 |
Why?
|
| Genomics | 1 | 2019 | 116 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 163 | 0.150 |
Why?
|
| Reminder Systems | 1 | 2018 | 11 | 0.150 |
Why?
|
| Insulin | 3 | 2018 | 310 | 0.150 |
Why?
|
| Communication Barriers | 1 | 2018 | 17 | 0.150 |
Why?
|
| Lipoproteins, LDL | 2 | 2015 | 36 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2018 | 46 | 0.140 |
Why?
|
| Choanal Atresia | 1 | 2017 | 1 | 0.140 |
Why?
|
| Microphthalmos | 1 | 2017 | 5 | 0.140 |
Why?
|
| Muscular Dystrophies | 1 | 2017 | 4 | 0.140 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 93 | 0.140 |
Why?
|
| Nose | 1 | 2017 | 22 | 0.140 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 481 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2017 | 509 | 0.130 |
Why?
|
| Lipids | 2 | 2014 | 195 | 0.130 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2017 | 77 | 0.130 |
Why?
|
| Lost to Follow-Up | 1 | 2015 | 3 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 623 | 0.130 |
Why?
|
| Mutation | 2 | 2017 | 817 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 41 | 0.120 |
Why?
|
| Indians, North American | 1 | 2019 | 511 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2017 | 624 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 439 | 0.110 |
Why?
|
| Pediatric Obesity | 1 | 2015 | 72 | 0.110 |
Why?
|
| Comorbidity | 1 | 2014 | 252 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 654 | 0.110 |
Why?
|
| Mice | 2 | 2020 | 4406 | 0.110 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2012 | 1 | 0.110 |
Why?
|
| Diet, Fat-Restricted | 1 | 2012 | 5 | 0.110 |
Why?
|
| Lactones | 1 | 2012 | 7 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 910 | 0.110 |
Why?
|
| Lipoprotein Lipase | 1 | 2012 | 10 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 357 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 279 | 0.100 |
Why?
|
| Disease Progression | 1 | 2014 | 450 | 0.100 |
Why?
|
| Risk | 1 | 2013 | 133 | 0.100 |
Why?
|
| Manometry | 1 | 2011 | 36 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 247 | 0.100 |
Why?
|
| Overweight | 1 | 2012 | 110 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2011 | 63 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 233 | 0.090 |
Why?
|
| Animals | 2 | 2020 | 9960 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2011 | 1216 | 0.070 |
Why?
|
| Quality of Life | 1 | 2011 | 464 | 0.070 |
Why?
|
| Prevalence | 2 | 2019 | 472 | 0.070 |
Why?
|
| Sex Factors | 2 | 2020 | 445 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2020 | 351 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2018 | 1091 | 0.060 |
Why?
|
| Oklahoma | 2 | 2019 | 973 | 0.060 |
Why?
|
| Diastole | 1 | 2022 | 22 | 0.050 |
Why?
|
| Meals | 1 | 2022 | 20 | 0.050 |
Why?
|
| Postprandial Period | 1 | 2022 | 41 | 0.050 |
Why?
|
| Dyslipidemias | 1 | 2021 | 31 | 0.050 |
Why?
|
| Maternal Exposure | 1 | 2020 | 16 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2020 | 37 | 0.040 |
Why?
|
| Acetylation | 1 | 2020 | 36 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 31 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 73 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2020 | 115 | 0.040 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2020 | 8 | 0.040 |
Why?
|
| Histones | 1 | 2020 | 90 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2020 | 90 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2020 | 130 | 0.040 |
Why?
|
| C-Peptide | 1 | 2018 | 8 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 148 | 0.040 |
Why?
|
| Autonomic Nervous System | 1 | 2019 | 110 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 330 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 700 | 0.040 |
Why?
|
| Fasting | 1 | 2018 | 77 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 390 | 0.040 |
Why?
|
| Heart | 1 | 2019 | 219 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2018 | 10 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2018 | 8 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 166 | 0.040 |
Why?
|
| Echocardiography | 1 | 2018 | 107 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2018 | 127 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 100 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2018 | 77 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 263 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 310 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2015 | 8 | 0.030 |
Why?
|
| Exercise | 1 | 2020 | 451 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 278 | 0.030 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2015 | 6 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 1475 | 0.030 |
Why?
|
| Peroxidase | 1 | 2015 | 37 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 665 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 205 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 354 | 0.030 |
Why?
|
| Apolipoprotein A-II | 1 | 2012 | 2 | 0.030 |
Why?
|
| Lipase | 1 | 2012 | 10 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2012 | 18 | 0.030 |
Why?
|
| Exons | 1 | 2012 | 41 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2012 | 38 | 0.030 |
Why?
|
| Heterozygote | 1 | 2012 | 64 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2012 | 67 | 0.030 |
Why?
|
| Pancreatitis | 1 | 2012 | 36 | 0.030 |
Why?
|
| Triglycerides | 1 | 2012 | 117 | 0.030 |
Why?
|
| Child Health Services | 1 | 2011 | 7 | 0.020 |
Why?
|
| Disorders of Sex Development | 1 | 2011 | 13 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 13 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 19 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 918 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2011 | 30 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 34 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 2264 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2011 | 129 | 0.020 |
Why?
|